Blueprint Medicines (BPMC) to Release Quarterly Earnings on Thursday

Blueprint Medicines (NASDAQ:BPMC) is anticipated to post its quarterly earnings results before the market opens on Thursday, February 20th. Analysts expect Blueprint Medicines to post earnings of ($0.68) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Blueprint Medicines Stock Up 2.0 %

Shares of NASDAQ BPMC opened at $103.56 on Thursday. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. Blueprint Medicines has a 52-week low of $72.24 and a 52-week high of $121.90. The business has a 50-day moving average price of $99.65 and a 200 day moving average price of $94.77. The stock has a market cap of $6.58 billion, a PE ratio of -49.08 and a beta of 0.62.

Insider Buying and Selling at Blueprint Medicines

In other news, insider Ariel Hurley sold 1,819 shares of the stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $93.26, for a total value of $169,639.94. Following the completion of the sale, the insider now owns 14,967 shares in the company, valued at $1,395,822.42. This represents a 10.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Kate Haviland sold 1,446 shares of Blueprint Medicines stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total value of $159,407.04. Following the transaction, the chief executive officer now owns 149,378 shares in the company, valued at $16,467,430.72. This represents a 0.96 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 49,851 shares of company stock valued at $4,984,696. Corporate insiders own 4.21% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on BPMC. StockNews.com upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. Wedbush reissued an “outperform” rating and set a $124.00 price target (down previously from $135.00) on shares of Blueprint Medicines in a research report on Monday, January 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a research note on Monday, January 13th. HC Wainwright reissued a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a research note on Friday, November 15th. Finally, JPMorgan Chase & Co. lifted their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Blueprint Medicines has an average rating of “Moderate Buy” and an average target price of $123.72.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.